Medcaptain Schedules 28 September Board Meeting to Approve H1 2026 Results and Consider Interim Dividend

Bulletin Express
Yesterday

Medcaptain Medical Technology Co., Ltd. (Medcaptain) announced that its board of directors will convene on 28 September 2026 to review and approve the Group’s interim financial results for the six months ended 30 June 2026. The agenda will also include discussion on the declaration and payment of an interim dividend, alongside other routine matters.

The board currently comprises nine directors: three executive directors (Mr. Liu Jie, Mr. Zhong Yaoqi and Mr. Yan Renzhong), three non-executive directors (Ms. Li Hui, Mr. Zhang Jiecheng and Dr. Zhou Yi) and three independent non-executive directors (Dr. Shao Liyang, Mr. Zhang Hanbin and Mr. Tam Man Hong). Chairman and executive director Mr. Liu Jie issued the notice from Hong Kong on 16 September 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10